This Article Full Text (PDF) References Alert me when this article is cited Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Add to Saved Citations Download to citation manager Request Permissions Request Reprints Add to My Marked Citations Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Asbury, A. K. Search for Related Content PubMed PubMed Citation Articles by Asbury, A. K. Social Bookmarking                   What's this?

New Concepts of Guillain-Barré Syndrome

Department of Neurology, University of Pennsylvania School of Medicine, Philadelphia, PA

Guillain-Barré syndrome is an acute autoimmune polyradiculoneuropathy with a clinical presentation of flaccid paralysis with areflexia, variable sensory disturbance, and elevated cerebrospinal fluid protein without pleocytosis. Although Guillain-Barré syndrome previously had been viewed as a unitary disorder with variations, it currently is viewed as a group of syndromes with several distinctive subtypes. These include the principal subtype prevalent in the Western world (acute inflammatory demyelinating polyradiculoneuropathy, and others, each with distinctive electrodiagnostic and pathologic features, including acute motor axonal neuropathy), acute motor-sensory axonal neuropathy, Miller Fisher syndrome, and perhaps others. The clinical and pathologic features of these Guillain-Barré syndrome subtypes are reviewed, and the role of antecedent infections, particularly Campylobacter jejuni gastroenteritis, and the role of antiganglioside antibody responses are reviewed with respect to pathogenesis. Treatment of Guillain-Barré syndrome includes both important supportive measures and immunotherapies, specifically high-dose intravenous immunoglobulin and plasma exchange. (J Child Neurol 2000;15:183-191).

CiteULike    Connotea    Del.icio.us    Digg    Reddit    Technorati    What's this?

This article has been cited by other articles:

				S Agrawal, D Peake, and W P Whitehouse Management of children with Guillain-Barre syndrome Arch. Dis. Child. Ed. Pract., December 1, 2007; 92(6): 161 - 168. [Full Text] [PDF]

				J Schessl, M Koga, K Funakoshi, J Kirschner, W Muellges, A Weishaupt, R Gold, and R Korinthenberg Prospective study on anti-ganglioside antibodies in childhood Guillain-Barre syndrome Arch. Dis. Child., January 1, 2007; 92(1): 48 - 52. [Abstract] [Full Text] [PDF]

				R. Korinthenberg, J. Schessl, J. Kirschner, and J. S. Monting Intravenously Administered Immunoglobulin in the Treatment of Childhood Guillain-Barre Syndrome: A Randomized Trial Pediatrics, July 1, 2005; 116(1): 8 - 14. [Abstract] [Full Text] [PDF]

				M. M. Ryan and E. C. Engle Topical Review: Acute Ataxia in Childhood J Child Neurol, May 1, 2003; 18(5): 309 - 316. [Abstract] [PDF]

				H Locht and K A Krogfelt Comparison of rheumatological and gastrointestinal symptoms after infection with Campylobacter jejuni/coli and enterotoxigenic Escherichia coli Ann Rheum Dis, May 1, 2002; 61(5): 448 - 452. [Abstract] [Full Text] [PDF]

				A. Alaedini and N. Latov A surface plasmon resonance biosensor assay for measurement of anti-GM1 antibodies in neuropathy Neurology, April 10, 2001; 56(7): 855 - 860. [Abstract] [Full Text] [PDF]